Pop Goes The IPO
This article was originally published in Start Up
Executive Summary
There have been several notable first-day gains during the current IPO window, but for a newly public biotech company, a big pop is no augur of long-term success. However, those initial gains do say a lot about how public biotech investors feel about the companies offered up in a particular IPO market.